{"contentid": 487897, "importid": NaN, "name": "First-in-class biologic could change the way asthma is treated", "introduction": "Full results from a Phase III trial of tezepelumab, an innovative biologic developed by Amgen and AstraZeneca, raise hopes for a breakthrough in the treatment of severe asthma.", "content": "<p>Full results from a Phase III trial of tezepelumab, an innovative biologic developed by Amgen (Nasdaq: AMGN) and AstraZeneca (LSE: AZN), raise hopes for a breakthrough in the treatment of severe asthma.</p>\n<p>Results from the NAVIGATOR trial show a statistically-significant and clinically meaningful-reduction in symptoms, compared to placebo, when added to standard of care.</p>\n<p>The data, which were presented at the annual meeting of the American Academy of Asthma Allergy &amp; Immunology, will form the basis of forthcoming regulatory submissions.</p>\n<p>After one year, adding the medicine to standard of care resulted in a 56% reduction in the annualized asthma exacerbation rate (AAER), regardless of the baseline eosinophil counts.</p>\n<h2>Tezepelumab development</h2>\n<p>While existing biologics in this area tend to target people who have asthma with eosinophilia - a high level of white blood cells - Astra and Amgen hope to differentiate their option by targeting the equally common non-eosinophilic form of the disease.</p>\n<p>The firms are also pursuing a relatively unique approach, with only Novartis (NOVN: VX) working on a candidate with the same mechanism of action. That candidate, CSJ117, is still in mid-stage development.</p>\n<p>Leading alternatives currently on the market include Sanofi&rsquo;s (Euronext: SAN) Dupixent (dupilumab), Roche (ROG: SIX) and Novartis&rsquo; Xolair (omalizumab) and AstraZeneca&rsquo;s Fasenra (benralizumab).</p>\n<p>Despite the crowded field, the market opportunity for tezepelumab is significant, given the size of the patient population.</p>\n<p>Under the terms of the firms&rsquo; 2012 collaboration agreement, AstraZeneca is leading on development of the biologic, and will share in the profits should it reach the market.</p>\n<p>Principal investigator Andrew Menzies-Gow called the results &ldquo;ground-breaking,&rdquo; given that many patients &ldquo;continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics.\"</p>\n<p>He added: \"Tezepelumab has the potential to transform treatment for a broad population of patients with severe asthma regardless of their type of inflammation, including those with and without an eosinophilic phenotype.\"</p>", "date": "2021-03-01 09:46:00", "meta_title": NaN, "meta_keywords": "asthma, biologic, tezepelumab, first-in-class, results, trial, Amgen, AstraZeneca, severe, treatment, change, treated, developed, Full, Phase, breakthrough", "meta_description": "Full results from a Phase III trial of tezepelumab, a first-in-class biologic developed by Amgen and AstraZeneca, raise hopes for a breakthrough in the treatmen", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-01 09:45:40", "updated": "2021-03-01 10:25:50", "access": NaN, "url": "https://www.thepharmaletter.com/article/first-in-class-biologic-could-change-the-way-asthma-is-treated", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_big.jpg", "image2id": "astrazeneca_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Respiratory and Pulmonary", "topic_tag": "Deals, Drug Trial, Licensing, Research", "geography_tag": "UK, USA", "company_tag": "Amgen, AstraZeneca", "drug_tag": "Dupixent, Fasenra, tezepelumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-01 09:46:00"}